| | Business Summary | | Cadus
Pharmaceutical
Corporation
(Cadus)
has
developed
several
proprietary
drug
discovery
technologies
that
address
many
of
the
limitations
of
traditional
drug
discovery
methods,
including
tools
used
to
screen
for
compounds
that
act
as
agonists
or
antagonists
to
cell
surface
receptors
and
tools
used
to
identify
ligands
to
targeted
orphan
receptors.
Since
July
30,
1999,
the
Company
has
been
seeking
to
license
its
technologies
and
otherwise
realize
value
from
its
assets;
and
use
a
portion
of
its
available
cash
to
acquire
technologies
or
products
or
to
acquire
or
invest
in
companies. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | KDUS
engages
in
the
identification
of
genomic
targets
in
human
cell
signaling
pathways
and
the
discovery
of
small
molecule
therapeutics
that
act
on
such
targets.
KDUS
has
developed
proprietary
drug
discovery
technologies
based
on
genetically
engineered
yeast
cells.
For
the
three
months
ended
3/01,
revenues
fell
86%
to
$100
thousand.
Net
income
totaled
$273
thousand
vs.
a
loss
of
$341
thousand.
Revenues
reflect
ceased
research
efforts.
Net
income
reflects
decreased
S/G/A
expenses. Recent Earnings Announcement
For
the
3
months
ended
06/30/2001,
after
tax
earnings
were
-171. (Preliminary; reported in thousands of dollars.) | | More
from
Market Guide: Significant
Developments |
| | |
| Position | | Russell Glass, 38 | Pres,
CEO, Director |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/k/kdus.ob.gif)